The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
Open accessAbstract
BACKGROUND: Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety profile of anacetrapib in patients with coronary heart disease or at high risk for coronary heart disease. Eligible patients who were taking a statin and who had an LDL cholesterol level that was consistent with that recommended in guidelines were assigned to receive 100 mg of anacetrapib or placebo daily for 18 months. The primary end points were the percent change from baseline in LDL cholesterol at 24 weeks (HDL cholesterol level was a secondary end point) and the safety and side-effect profile of anacetrapib through 76 weeks. Cardiovascular events and deaths were prospectively adjudicated. RESULTS: A total of 1623 patients underwent randomization. By 24 weeks, the LDL cholesterol level had been reduced from 81 mg per deciliter (2.1 mmol per liter) to 45 mg per deciliter (1.2 mmol per liter) in the anacetrapib group, as compared with a reduction from 82 mg per deciliter (2.1 mmol per liter) to 77 mg per deciliter (2.0 mmol per liter) in the placebo group (P<0.001)--a 39.8% reduction with anacetrapib beyond that seen with placebo. In addition, the HDL cholesterol level increased from 41 mg per deciliter (1.0 mmol per liter) to 101 mg per deciliter (2.6 mmol per liter) in the anacetrapib group, as compared with an increase from 40 mg per deciliter (1.0 mmol per liter) to 46 mg per deciliter (1.2 mmol per liter) in the placebo group (P<0.001)--a 138.1% increase with anacetrapib beyond that seen with placebo. Through 76 weeks, no changes were noted in blood pressure or electrolyte or aldosterone levels with anacetrapib as compared with placebo. Prespecified adjudicated cardiovascular events occurred in 16 patients treated with anacetrapib (2.0%) and 21 patients receiving placebo (2.6%) (P = 0.40). The prespecified Bayesian analysis indicated that this event distribution provided a predictive probability (confidence) of 94% that anacetrapib would not be associated with a 25% increase in cardiovascular events, as seen with torcetrapib. CONCLUSIONS: Treatment with anacetrapib had robust effects on LDL and HDL cholesterol, had an acceptable side-effect profile, and, within the limits of the power of this study, did not result in the adverse cardiovascular effects observed with torcetrapib. (Funded by Merck Research Laboratories; ClinicalTrials.gov number, NCT00685776.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in humans, elevated cholesterol levels are a major risk factor for the development of cardiovascular disease (Cannon et al., 2010).”
From Population genomics reveal recent speciation and rapid evolutionary adaptation in polar bears (2014) · cites this paper as Cannon et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citationIntensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationPedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Thompson, A. (2008) · JAMA · doi:10.1001/jama.299.23.2777 · Cited by 498
Forrest, M. J., Bloomfield, D. M., Briscoe, R. J., Brown, P. N., Cumiskey, A., Ehrhart, J., Hershey, J. C., Keller, W. J., Ma, X., McPherson, H. E., et al. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.229 · Cited by 293
Krishna, R., Anderson, M. S., Bergman, A. J., Jin, B., Fallon, M. S., Côté, J., Rosko, K., Chavez-Eng, C. M., Lutz, R., Bloomfield, D. M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61813-3 · Cited by 275
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 752
Twenty-five years of statins: where do we go from here?
Gotto, A. M., & Moon, J. E. (2015) · Clinical Lipidology · doi:10.2217/clp.14.62 · Cited by 2
Self-citationCommentary: Lipoprotein(a) and atherosclerosis
Clarke, R. (2011) · International Journal of Epidemiology · doi:10.1093/ije/dyr015 · Cited by 2
Sanina, C., Bockeria, O. L., Wiley, K. A., & Feig, J. E. (2018) · Wiley eBooks · doi:10.1002/9781119283539.ch1 · Cited by 2
Wierzbicki, A. S. (2014) · Cardiogenetics · doi:10.4081/cardiogenetics.2014.4672 · Cited by 1
HIGH-DENSITY LIPOPROTEINS AND CARDIOVASCULAR DISEASE
Nicholls, S. J., Brown, H., & Bubb, K. J. (2020) · EMJ Cardiology · doi:10.33590/emjcardiol/20-00038 · Cited by 1
Zhang, J., Chen, Y., Li, J., Jia, H., & Lv, Z. (2025) · Journal of Clinical Question · doi:10.69854/jcq.2025.0030 · Cited by 2
Cholesteryl Ester Transfer Protein Inhibitors: State of the Science
Nejabat, M., Katsiki, N., Mukherjee, D., Hadizadeh, F., & Sahebkar, A. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02317-5 · Cited by 1
Bajnok, L. (2014) · Orvosi Hetilap · doi:10.1556/oh.2014.29797 · Cited by 1
The heart of the matter of opinion and evidence: the value of evidence-based medicine.
Masvidal, D., & Lavie, C. J. (2012) · PubMed Central · Cited by 1
News from the literature: Focus on joint ESC/EAS dyslipidemia guidelines
Stock, J. K. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.09.042 · Cited by 1
Medical angioplasty - Hope and expectations: An optimistic overview
Abdul-Mohsen, M. (2011) · Journal of Family and Community Medicine · doi:10.4103/2230-8229.90007 · Cited by 1
Actualización en el manejo del colesterol hdl bajo
Rigotti, A. (2012) · Revista Médica Clínica Las Condes · doi:10.1016/s0716-8640(12)70369-3 · Cited by 1
Novel Hypolipidemic Agents: Focus on PCSK9 Inhibitors
Manolis, A. S., Manolis, T. A., & Melita, H. (2013) · Hospital chronicles/Hospital Chronicles · doi:10.2015/hc.v9i1.578 · Cited by 1
Statins and CETP Inhibitors: Anacetrapib and Evacetrapib: The Last Hope?
Nicholls, S. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_6 · Cited by 1
Effects of Evacetrapib Administered as Monotherapy or in Combination With Statins
Steen, R. B. D. L., & Cannon, C. P. (2012) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0645 · Cited by 1
Self-citationBurchardt, P., Zawada, A. E., & Wierusz‐Wysocka, B. (2012) · PubMed · Cited by 1
What does the future hold for cholesteryl ester transfer protein inhibition?
Arsenault, B. J., Boyer, M., & Kastelein, J. J. P. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000248 · Cited by 1
Parhofer, K. G. (2013) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-013-1050-6 · Cited by 1
Lipid Lowering in Coronary Artery Disease
Ray, K. K., & Cannon, C. P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2358-8.00010-3 · Cited by 1
Self-citationSafety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
Toth, P. P. (2011) · Yearbook of Endocrinology · doi:10.1016/j.yend.2011.06.036 · Cited by 1
Role of Conventional Risk Factors in Genetic Susceptibility to Cardiovascular Diseases
Swerdlow, D. I., Michail, M., & Zacharias, K. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803312-8.00008-2 · Cited by 2
LDL-C-Senkung — „mechanism matters“
Medizin, S. (2016) · CardioVasc · doi:10.1007/s15027-016-0909-8 · Cited by 1
Wang, X., Hao, L., Xu, X., Li, W., Liu, C., Zhao, D., & Cheng, M. (2017) · Molecules · doi:10.3390/molecules22101658 · Cited by 1
Cholesteryl Ester Transfer Protein Inhibitors – Future Soon to be REVEALed
Huggins, C., Charolidi, N., & COCKERILL, G. W. (2015) · European Cardiology Review · doi:10.15420/ecr.2015.10.01.64 · Cited by 1
Drug discovery and development: An overview of modern methods and principles
Blass, B. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817214-8.00001-4 · Cited by 1
Why and when should be lipoprotein(a) level measured?
Broncel, M., & Broncel, M. (2023) · Exploration of Cardiology · doi:10.37349/ec.2023.00015 · Cited by 1
Bayesian Interim Inference of Probability of Clinical Trial Success
Wang, M., & Li, G. Y. (2013) · Springer proceedings in mathematics & statistics · doi:10.1007/978-1-4614-7846-1_12 · Cited by 1
Reverse Cholesterol Transport in HDL Metabolism
Villard, E. F., & Guérin, M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-407867-3.00004-4 · Cited by 1
Diabetes and the Cardiovascular System
Cohen, P., & Plutzky, J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6705-2_41 · Cited by 1
Pende, A., & Denegri, A. (2012) · InTech eBooks · doi:10.5772/31565 · Cited by 1
Targeting High-Density Lipoprotein and Triglycerides in Statin-Treated Patients with Diabetes
Bonds, D. E. (2011) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-011-0209-x · Cited by 1
Suckling, K. E. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.667402 · Cited by 1
Almanac 2013: stable coronary artery disease
Islam, S., & Timmis, A. (2013) · Heart · doi:10.1136/heartjnl-2013-304593 · Cited by 1
Controversies in dyslipidaemia management
Stock, J. K. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.12.036 · Cited by 1
Health Care Guideline Lipid Management in Adults
Woolley, T. W., Groen, S., Kofron, P. M., Leslie, S., Myers, C. D., Needham, R. H., Peters, J., Reddan, J. G., & Sorge, L. A. (2013) · Cited by 1
Kumar, A., Acharya, A., Nandi, D., Sharma, N., & Chitkara, E. (2016) · International Journal of Pharmacy and Pharmaceutical Sciences · Cited by 1
Advances in Hypercholesterolemia
Pirillo, A., Norata, G. D., & Catapano, A. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12435-7 · Cited by 1
Low-density lipoprotein cholesterol variability increases the risk of cardiovascular events
Corsini, A. (2016) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000462 · Cited by 1
Therapies Targeting HDLc Levels and HDL Function
Vitali, C., & Cuchel, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812513-7.00012-4 · Cited by 1
Lipids in Coronary Heart Disease
Martin, S. S., Joshi, P. H., & Michos, E. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802385-3.00007-3 · Cited by 2
Nicholls, S. J., & Nelson, A. J. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-00323-3 · Cited by 1
Lipid Disorders and Familial Hypercholesterolaemia
Pottle, A. (2019) · Springer eBooks · doi:10.1007/978-3-319-99817-6_57 · Cited by 1
Enhancement of HDL by Policosanol
Cho, K. (2019) · Springer eBooks · doi:10.1007/978-981-13-7383-1_3 · Cited by 1
Enkhmaa, B., Anuurad, E., Zhang, W., & Berglund, L. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_3 · Cited by 1
HDL colesterol, protector de enfermedad cardiovascular: calidad vs. cantidad
Stoll, A. I. (2019) · Revista de Investigación de la Universidad Norbert Wiener · doi:10.37768/unw.rinv.05.01.011 · Cited by 1
Dusty Punch Cards and an Eternal Enigma: High-Density Lipoproteins and Atherosclerosis
Kleber, M. E., Grammer, T. B., Kassner, U., Silbernagel, G., & März, W. (2014) · Drugs · doi:10.1007/s40265-014-0189-5 · Cited by 1
Dalcetrapib: turning the tide for CETP inhibition?
Stroes, E. S. G., & van Wijk, D. F. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61421-9 · Cited by 1
The cholesterol ester transfer protein inhibitor, anacetrapib
Jialal, I., & Kaur, J. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283474ce1 · Cited by 1
Update on therapies targeting HDL
Virani, S. S., & Ballantyne, C. M. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834d16f0 · Cited by 1
(2010) · Circulation · doi:10.1161/cir.0b013e318202056b · Cited by 1
Modulation of vascular inflammation: cell type specific effects by ADAMs and HDL
van der Vorst, E. P. C. (2015) · doi:10.26481/dis.20150521ev
Dyslipidemia and Its Management in Type 2 Diabetes
Betteridge, D. J. (2014) · Wiley eBooks · doi:10.1002/9781118337967.ch7
Secondary prevention in heart failure: a special focus on aspirin, statins and exercise
Lewinter, C. (2013) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Montes, A. (2012) · CommonKnowledge Research Repository (Pacific University Oregon)
The Role of CETP Modulation and Inhibition in the Progression of Coronary Heart Disease
Davidson, M. H., Nicholls, S. J., Rosenson, R. S., & Ballantyne, C. M. (2016) · The Medical Roundtable Cardiovascular Edition
Self-citationEnhancement of HDL Formation and Normalization of Intravascular HDL Remodeling
Kontush, A., & Chapman, M. J. (2011) · Wiley eBooks · doi:10.1002/9781118158678.ch11
Drugs that affect lipid metabolism
Nestel, P. J. (2012) · Side effects of drugs annual · doi:10.1016/b978-0-444-59499-0.00044-1
Kindermann, L. (2014) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-10852
Principles of Primary and Secondary Prevention of Cardiovascular Disease
Eapen, D. J., Ghasemzadeh, N., Bellam, N., Bhatia, N. K., Valiani, K., Shen, J., VanDam, R. J., Flueckiger, P. B., Molloy, D. L., Kay, J., et al. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_53
Medical Treatment of Stable Angina
Willerson, J. T., Ferguson, J. J., & Patel, D. D. (2015) · Cardiovascular medicine · doi:10.1007/978-1-4471-2828-1_17
Prévention du risque cardiovasculaire : faut-il bloquer la CETP ?
Krempf, M. (2013) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(13)70717-x
Atherosclerotic Plaque Imaging for Evaluation of HDL Targeting Therapy
Kataoka, Y., & Nicholls, S. J. (2014) · Journal of the Japanese Coronary Association · doi:10.7793/jcoron.20.033
Brown, W. V., Bays, H. E., Maki, K. C., & Wild, R. A. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.10.001
Is there a future for CETP-inhibitor therapy?
Robinson, J. G. (2011) · Clinical Investigation · doi:10.4155/cli.11.10
Almanac 2013: stable coronary artery disease
Islam, S., & Timmis, A. (2013) · Wiener klinische Wochenschrift · doi:10.1007/s00508-013-0473-5
Farnier, M. (2012) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(12)70354-1
Anacetrapib: potential for the prevention and treatment of coronary heart disease
Cannon, C. P., Steen, D. L., & Khera, A. V. (2013) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s27769
Self-citationNewer antiatherosclerosis treatment strategies
Aggarwal, A., & Singh, S. (2011) · Heart Asia · doi:10.1136/ha.2010.003129
Comprehensive Lipid Management in the Coronary Artery Disease Patient
Amin, N. P., Blaha, M. J., Chow, G. V., Blumenthal, R. S., & Ashen, M. D. (2011) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-011-0191-3
Intracoronary IVUS for Evaluation of Atherosclerosis Progression
Uno, K., Kataoka, Y., Puri, R., & Nicholls, S. J. (2012) · Current Cardiovascular Imaging Reports · doi:10.1007/s12410-012-9141-9
Examining controversies and new frontiers in lipid management
Nicholls, S. J. (2014) · Clinical Lipidology · doi:10.2217/clp.14.38
LDL das böse, HDL das gute Fett
Steffens, D., Bramlage, P., & Rauch‐Kröhnert, U. (2014) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Rees, A. (2014) · The British Journal of Diabetes · doi:10.15277/bjdvd.2014.003
Cholesteryl ester transfer protein inhibition and endothelial function: enough with the surrogates
Shah, P. K. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs040
Neue Entwicklungen in der Lipidtherapie
Parhofer, K. G. (2012) · Der Diabetologe · doi:10.1007/s11428-012-0892-3
Anninos, H., & Manolis, A. S. (2012) · Hospital chronicles/Hospital Chronicles
Bartas, R. (2012) · African Journal of Pharmacy and Pharmacology · doi:10.5897/ajpp11.887
Isaza, D., Gómez, M. Z., & Gómez, J. R. M. (2013) · Revista Digital Palabra (Universidad Pontificia Bolivariana)
Henderson, R. A., & Timmis, A. (2011) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2011.09.012
New targets and developments in lipoproteins control
Norata, G. D. (2013) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s34904
Klose, G., & Hambrecht, R. (2013) · Der Kardiologe · doi:10.1007/s12181-013-0505-4
Альманах-2013: стабільна ішемічна хвороба серця*
Islam, S., & Timmis, A. (2014) · Український кардіологічний журнал
How Do We Approach Low High-density Lipoprotein Cholesterol in 2011?
Godfrey, E., & Halcox, J. (2011) · European Cardiology Review · doi:10.15420/ecr.2011.7.4.257
HDL therapies — past, present and future
Barbaras, R. (2015) · JOURNAL OF MEDICINES DEVELOPMENT SCIENCES · doi:10.18063/jmds.2015.02.005
Anacetrapib for Lipid Management: Safety in Numbers
Gore, J. M. (2010) · Journal watch · doi:10.1056/jc201011170000001
1. Coronary Intervention and Intensive Risk Control
Yamagishi, M. (2013) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.102.649
Therapy to Manage Low High-Density Lipoprotein Cholesterol and Elevated Triglycerides
Davidson, M. H. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00025-4
Self-citationNovel therapeutic approaches to prevention and regression of atherosclerosis
Chyu, K., & Shah, P. K. (2012) · CRC Press eBooks · doi:10.3109/9781841848549.037
Gouni‐Berthold, I. (2016) · CardioVasc · doi:10.1007/s15027-016-1033-5
Dietary associations that may reduce metabolic syndrome risk in Mexican young adults
Mosley, M. A. (2012) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
The Effect of Cardiovascular Risk Factors on the Coronary Circulation
Valenzuela-García, L. F., Matsuzawa, Y., & Lerman, A. (2017) · Springer eBooks · doi:10.1007/978-1-4471-5245-3_6
Clinical and Angiographic profile of Premature Coronary Heart Disease.
Ranganathan, K. (2012)
Novel therapies for dyslipidemia
Wierzbicki, A. S. (2013) · doi:10.2217/fmeb2013.13.9
Liang, Y., Cui, Y., Cannady, E. A., Small, D. S., Xin, P., Wang, M., Jin, J. J., Zhao, X., & Suico, J. G. (2018) · International Journal of Pharmacokinetics · doi:10.4155/ipk-2017-0017
Fettstoffwechsel; Lipidsenker - Pharmakotherapie bei Fettstoffwechselstörungen
Keller, C. (2013) · Elsevier eBooks · doi:10.1016/b978-3-437-42523-3.00025-7
Stable Ischemic Heart Disease/Chronic Stable Angina
Newby, D. E., & Fox, K. A. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00008-4
Emerging Lipid-Lowering Therapies in Secondary Prevention
Mahtta, D., Virani, S. S., & Bavry, A. A. (2019) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-019-0607-z
THE ROLE OF HYPERCHOLESTEROLEMIA IN POPULATION MORBIDITY NOSOLOGICAL STRUCTURE DEVELOPMENT
GAZHIEVA, Y. G. A. (2019) · The Bulletin of Contemporary Clinical Medicine · doi:10.20969/vskm.2019.12(1).45-49
Metadata
- Authors
- Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., Zafarino, J., Mitchel, Y., & Barter, P.
- Affiliations
- Brigham and Women's Hospital (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Radiant Research (United States) (US)
- University of Utah (US)
- The Heart Research Institute (AU)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-16
- Volume
- 363
- Issue
- 25
- Pages
- 2406-2415
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2090464684
- Cited by
- 749
- References
- 17
- Citations by year
- 2026: 13 · 2025: 7 · 2024: 13 · 2023: 13 · 2022: 16 · 2021: 18 · 2020: 18 · 2019: 21 · 2018: 26 · 2017: 54 · 2016: 68 · 2015: 83 · 2014: 83 · 2013: 92 · 2012: 116
- FWCI
- 107.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- anacetrapib, cholesteryl ester transfer protein inhibitors, coronary artery disease, LDL cholesterol lowering, HDL cholesterol, statin combination therapy, cardiovascular safety, cardiovascular events, drug safety, high-risk patients, lipid-lowering therapy, blood pressure, electrolytes, aldosterone, Bayesian hierarchical model, cardiovascular hospitalization
- MeSH terms
- Adult, Aged, Anticholesteremic Agents, Bayes Theorem, Combined Modality Therapy, Coronary Disease, Double-Blind Method, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Oxazolidinones, Cholesterol Ester Transfer Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
